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THOUGH Ehrlich carcinoma is not subject to homograft rejection in most
strains of mice, it is known to provoke after allogeneic transplantation an immune
response which has been reported to be humoral (Hartveit, 1965) as well as cellular
(Wheatley and Ambrose, 1964; Stuart and el Hassan, 1964a and b). Wheatley
and Easty (1964) have demonstrated that suppression of immunological respon-
siveness of mice inhibits the growth and invasiveness ofEhrlich ascites carcinoma
(EAC). There have been recent reports on the suppression of both primary and
secondary immune responses of mice to sheep (Markley et al., 1967) and rat
(Spreafico and Lerner, 1967) erythrocytes by prior intraperitoneal injection and
to human y globulin by prior intravenous injection (Gamble, 1966) of phyto-
haemagglutinin (PHA). This paper presents the results of intraperitoneal and
intramuscular injections of PHA on the growth ofEAC and Ehrlich subcutaneous
solid carcinoma (ESC) in mice.
MATERIALS AND METHODS
The EAC was maintained by serial intraperitoneal passage in mice (20-25 g.)
obtained from the Commonwealth Serum Laboratories, C.S.L., Melbourne. This
mouse colony has been raised by closed breeding for over 20 years. To avoid
any effect ofthe sex ofthe recipient mice on the growth ofthe Ehrlich carcinoma
(Thunold, 1967), only female mice were used. In all the experiments, irrespective
of whether the tumour was transplanted subcutaneously (in the right flank) or
intraperitoneally, the tumour inoculum contained 2-5 x 106 EAC cells. Prelimi-
nary investigations had shown that intraperitoneal or subcutaneous inoculation
of 2-5 x 106 EAC cells result in 100% tumour " takes " in the C.S.L. mice and
also that all these mice bearing EAC die in 18 ± 2 days.
The mice were divided into groups of 5 and each group was kept in one cage for
3 weeks before tumour inoculation and throughout the experiment. The mice
were weighed three times a week and after tumour transplantation were also
examined daily. Autopsy was performed on all ESC-bearing mice. The solid
tumours were weighed to the nearest 0 01 g. and several cross sections ofthe solid
tumour and representative areas of all internal organs and any tissue appearing
abnormal were examined histologically. Throughout these experiments " Well-
come " brandphytohaemagglutinin (WellcomeResearchLaboratories, Beckenham,
England), a sterile lyophilized extract ofthe seeds ofPhaseolus vulgaris was used.
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This phytohaemagglutinin is a protein associated with a polysaccharide moiety.
For injecting mice, the PHA was reconstituted to a concentration of 20 mg./ml.
(unless otherwise stated) with distilled water or, for use in experiments where
EAC cells were incubated in vitro, it was reconstituted with isotonic saline. As
controls for PHA treatment, there were groups of mice or samples of EAC cells
which were treatedwith isotonic saline,Neopeptonesolution(10%w/vNeopeptone,
Difco, in isotonic saline), Dextraven (solution of 10% w/v dextran having an
average molecular weight of 150,000 in 5% w/v dextrose, Benger Laboratories),
or which were untreated. Strict sterile conditions were maintained during all
injections, tumour transplantation and EAC cell incubation procedures. Viability
ofEAC cells was assessed by dye exclusion test using 0.5% trypan blue in isotonic
saline.
RESULTS
Experiment I
In the first experiment, at various intervals before tumour inoculation mice
were injected intraperitoneally with 1 ml. of either an aqueous solution of PHA
(groups 1 to 4) or Neopeptone solution (groups 5 to 6), Dextraven (groups 10 to
12) or isotonic saline (groups 7 and 8). The animals of group 9 received tumour
cells only. After tumour transplantation, mice in group 4 received further
intraperitoneal injections of PHA (10 mg./ml.): 1 ml. at 24 hours followed by a
total of 5 injections, each of 0-5 ml. at 48 hour intervals. Table I shows, for each
TABLE I.-Effect of Intraperitoneal Injection ofPHA and other Materials on
the Growth of EAC in C.S.L. Mice
Pretransplantation
treatment of mice Mean post-transplantation
_________________________AMean survival weights of mice (g.)
Mice of Time of mice ,A_ _ _
group no. Material (hours) (days) Day 0 Day 7 Terminal
1 . PHA 72 . 17-6±2-3 22-6±2-2 26-6±2-1 41-6±4-8
2 PHA 24 . 14-3±1-7t. 21-8±2-5 25-6±2-5 28-5±3-7t
3 . PHA 0 5 . 14-0±1-2t. 22-9±1-5 22-9±1-5 27-6±4-it
4 . PHA 0.5* 13-6±0-6t. 25-6±1-0 27-0±2-7 30-3±3-3t
5 . Neopeptone 72 . 13-8±2-8t. 25-7±2-3 27-0±4-0 34-4±7-7
6 . Neopeptone 0-5 . 13-0±0-8 . 25-9±3-2 27-0±3-0 31-0±5-6t
7 . Saline 72 . 19-0±0-0 . 23-8±1-4 25-8±1-8 39-6±7-3
8 . Saline 0-5 . 18-2±1-1 . 21-6±2-1 25-0±2-7 35-8±7-5
9 . No treatment . 18-4±1-3 . 23-7±1-4 28-0±2-5 41-6±5-8
10 . Dextraven 72 . 17-2±2-8 . 24-4±1-5 28-2±2-3 43-0±8-2
11 . Dexraven 24 . 16-2±1-1 . 23-8±2-0 28-4±1-8 45-0±6-8
12 . Dextraven 0-5 . 17-3±1-5 . 26-0±1-7 30-5±3-8 51-0±6-6
* Received further injections of PHA, see text.
t Significantly different from the corresponding value for group 9.
group ofmice, the details ofthe treatments, the mean survival time, and the mean
weights of the mice recorded immediately before tumour transplantation, at
7 days after tumour transplantation and at the weighing nearest to the time of
death (terminal weight). The mice treated 24 hours and 0-5 hour before tumour
inoculation with PHA (groups 2 and 3) or 72 and 0-5 hours before tumour inocu-
lation with Neopeptone (groups 5 and 6) died earlier (P < 0-005). Continuation
of PHA injections after tumour inoculation (group 4) did not reduce survival time
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any further. The mice which died early had a lower terminal body weight and
less distended abdomen suggesting that death was not due to faster growth of
EAC.
Experiments II and III were undertaken to ascertain whether the early death
of the mice belonging to groups 2 and 6 was due to the effect of PHA and
Neopeptone on the host or was brought about by the action ofthese two substances
on the tumour cells.
Experiment II
Aliquots of 2-5 x 106 cells were incubated for one hour at room temperature
with 1 ml. of saline solution of PHA or 1 ml. of Neopeptone solution, Dextraven
or isotonic saline. The cells were repeatedly washed with saline. At least 95%
EAC cells were viable before intraperitoneal inoculation into mice. The mean
survival time and the mean body weight ofeach group ofthese mice are shown in
Table II. The mice receiving PHA or Neopeptone treated EAC cells survived
longer than the mice in the control groups 14, 16 and 17.
TABLE II.-Growth in C.S.L. Mice of EAC Cells Pretreated with PHA
and other Materials
Mean post-transplantation
EAC cells Mean weights of mice (g.)
Mice of incubated in Survival of
group no. vitro with mice (days) Day 0 Day 7 Terminal
13 . PHA 27-0±2-0 22-6-1-5 23-2+1-4 43-0±9-6
14 . Saline . 19-2$3-8 . 22-1±1-5 23-4+1-3 34-2±4-9
15 Neopeptone 26-0* 21-6+1-3 23-2+1-8
16 . Dextraven . 19-1+2-5 . 24-3±2-3 26-3±1-8 40-3±7-2
17 . No treatment . 21-5±1-0 24-8±1-8 27-5±1-3 46-3+4-8
* Mean survival time of 2 mice. The remaining 3 mice in group 15 were alive for more than 250
days (at the time of submission of this paper) after intraperitoneal inoculation of EAC cells with no
visible sign of tumour.
Experiment III
Four groups of mice were injected intraperitoneally with 1 ml. of aqueous
PHA, isotonic saline, Neopeptone solution or Dextraven 0-5 hour before tumour
inoculation and a fifth group with tumour cells only. From 24 hours after tumour
transplantation till the death of the mice, smears of peritoneal exudate were
obtained every day from each group and were examined after Leishman staining.
On any given day after tumour inoculation, the number of dividing tumour cells
was similar in all the groups. In the mice injected with PHA or Neopeptone,
from after the seventh day after tumour inoculation, 1 to 3% ofEACcellscontained
a large cytoplasmic vacuole displacing the nucleus to the periphery. Cells with
this morphology were seen onlyrarely inthe exudate from the other groups ofmice.
From the fourth to the tenth day after tumour inoculation, the EAC cells from the
mice which received PHA had generally more basophilic cytoplasm and more
prominent nucleoli compared with the EAC cells obtained on the corresponding
days from any other groups of mice. The smears prepared, at 24 hours after
transplantation, from mice injected with PHA or Neopeptone, contained 70-90%
polymorphonuclear leucocytes which decreased to the level observed in the other
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groups of mice (i.e. less than 1%) by about the eighth post transplantation day.
In the PHA injected mice there was, however, a sharp reduction in the proportion
of polymorphonuclear leucocytes in the smears (i.e. to the level of 5-10% of all
cells counted) at 72 hours after transplantation.
Experiment IV
Experiment IV was designed to study the effect of intramuscular injections
of PHA, Dextraven and Neopeptone solutions on the survival of mice bearing
EAC. Every animal of 4 groups of mice was injected intramuscularly either
with 1 ml. of PHA, Neopeptone solution, Dextraven or isotonic saline 0 5 hour
before intraperitoneal inoculation of EAC cells. A fifth group of mice received
EAC cells only. In a sixth group of mice 0.1 ml. (1 mg.) of PHA was injected
intramuscularly every 24 hours for 7 days in addition to the injection of 1 ml.
ofPHA before the inoculation ofEAC. There was no prolongation or shortening
of survival time in any ofthese groups ofmice.
Experiments V and VI
Experiments V and VI were undertaken to study the effect of intraperitoneal
injections of PHA, Neopeptone solution, and Dextraven on the ESC which grows
at a slower rate and kills tumour-bearing mice after a much longer period than
does EAC. In ExperimentV each animal of4groups ofmice wasintraperitoneally
injected with either 1 ml. of PHA, Neopeptone solution, Dextraven or isotonic
saline 0.5 hour before subcutaneous inoculation of EAC cells into their right
flank. The mice were observed until their death. There was a wide range of
variation in the survival time within each group and there was no significant
difference in the mean survival time ofthe mice for each ofthe groups. Many of
the tumours ulcerated and became infected, and some mice developed terminal
ascites. It appeared that both ulceration and formation of ascites hastened
death in these mice. Therefore in Experiment VI, 4 groups of mice were treated
exactly in the same way as those groups in Experiment V but all mice were killed
on the fifteenth day after tumour transplantation. No tumour had ulcerated
at this time. From Table III it can be seen that the mean tumour weights in the
TABLE III.-Effect of Intramuscular Injection ofPHA and other Materials
on the Growth ofESC in C.S.L. Mice
Pre-transplantation
treatment of mice: Mean tumour weights (g.)
Mice of (Material injected 15 days after subcutaneous
group no. intraperitoneally) transplantation
23 . PHA . 045±014
24 Saline 0*38±0-17
25 . Neopeptone . 034i0-10
26 . Dextraven . 0*22±0*17
groups ofmice which received PHA, Neopeptone or Dextraven are not significantly
different from the mean tumour weight in the saline treated group ofmice. Three
of the 5 mice which received Dextraven had free ascites tumour cells as well as
tiny deposits of solid Ehrlich tumour in their peritoneal cavity. These 3 mice
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had smaller solid tumours at the site of tumour inoculation and also showed
metastases: 2 ofthe mice had metastases in the lungs and the third mouse showed
metastases in the ipsilateral inguinal lymph node. Two of the 5 mice which
received Neopeptone solution and one of the 5 mice which received PHA showed
metastases in their kidneys. Histological examination of the solid tumours
revealed more polymorphonuclear leucocytes in and around the tumour tissue in
the mice which received Neopeptone solution. No other specific histological
change could be detected in any other tissue of any particular group of mice.
These experiments were each repeated several times using different batches
of the " Wellcome " PHA. All these samples of PHA consistently caused
agglutination of EAC cells and of the red and white blood cells, and were capable
ofinducing mitosis andblast celltransformation in cultures ofhuman lymphocytes.
Though the results of the experiments with different batches of PHA were essen-
tially the same as the results presented above (Experiments I, III, IV, V and VI)
the inhibitory effect ofPHA when incubated in vitro for 1 houratroom temperature
with EAC cells (Experiment II) varied from one preparation of PHA to another.
Some batches of PHA consistently failed to show any inhibitory effect whereas
other preparations consistently prolonged the survival of EAC-inoculated mice.
PAS-positive material could be detected on the surface of PHA-treated EAC
cells, irrespective of whether the particular preparation of PHA possessed any
inhibitory effect on the growth of EAC cells.
DISCUSSION
The earlier death of mice which, preceding intraperitoneal inoculation of EAC
cells, received intraperitoneal PHA within 24 hours or intraperitoneal Neopeptone
solution within 72 hours seems to be associated with the concomitant poly-
morphonuclear response in the peritoneal cavity. This was supported by the
observations: that intraperitoneal injection of materials (Dextraven or isotonic
saline) which did not cause any polymorphonuclear leucocytic response did not
affect the survival time of EAC-inoculated mice; that intraperitoneal inoculation
of EAC cells, 72 or (as observed in an earlier experiment) 120 hours after PHA
injection-that is when the intensity of polymorphonuclear cellular response in
the peritoneal exudate had sharply decreased-did not affect the survival time
of these mice; and that intramuscular injections of PHA or Neopeptone did not
also alter the.survival of EAC-bearing mice. The variation in the inhibition of
EAC cells after incubation in vitro with PHA in our experiments may be due
either to the presence of different types of phytohaemagglutinins with varying
tumour inhibitory activity (Nungester and Van Halsema, 1953) in different
batches of the " Wellcome " PHA, or to the presence in some of these rather
crude preparations of cytotoxic substances not associated with the agglutinating,
mitogenic and blast cell-transforming activities of PHA. The discrepancy in
the reports on the effect of PHA on transplanted rodent tumours (Nungester
and Van Halsema, 1953; Rubio and Unsgaard, 1966; Robinson, 1967) may thus
be due to the use of different preparations of PHA or to the administration of
PHA by different routes. The action of Dextran in increasing the incidence of
successful implantation of tumour cells and metastasis has already been demon-
strated by Garvie and Matheson (1966); the role of PHA and Neopeptone on
tumour metastasis is at present under investigation.
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SUMMARY
Intraperitoneal or intramuscular injections of a phytohaemagglutinin (PHA)
into mice had no protective effect against the growth ofEhrlich ascites carcinoma
or Ehrlich solid subcutaneous carcinoma. Under certain circumstances, intra-
peritoneal injections of PHA resulted in early death of the mice bearing Ehrlich
ascites carcinoma. Incubation of Ehrlich ascites carcinoma cells with some
preparations of PHA before inoculation into mice was observed to inhibit the
growth of the tumour.
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